1 week ago
1
SyhinStas/iStock via Getty Images
Ionis Pharmaceuticals (NASDAQ:IONS) added ~17% in the premarket on Tuesday after the company announced that its RNA-targeted therapy olezarsen succeeded in two late-stage trials for severe hypertriglyceridemia, a condition characterized by high triglycerides in blood.
Citing topline data from its
English (US) ·